Page 76 - Roche Diagnostics News Today

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its plans to launch the SARS-CoV-2 & Flu A/B Rapid Antigen Test for professional use in markets accepting the CE Mark by the beginning of January. Roche also intends to file for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) in ...

The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient

DUBLIN--(BUSINESS WIRE)--The "Digital Diabetes Management Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.The global digital diabetes management market is expected to grow from $6.17 billion in 2020 to $7.37 billion in 2021 at a compound annua...

03.12.2021 - Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutionsThree new testing kits are among the first to ... Seite 1

By Brenna Hughes Neghaiwi

Roche, the worlds largest biotech company, announced Friday that TIB Molbiol, which was...

Roche's newly acquired subsidiary TIB Molbiol has developed three new test kits to help researchers detect mutations in the new Omicron variant of coronavirus, Roche said on Friday.

ZURICH—Roche's newly acquired subsidiary TIB Molbiol has developed three new test kits to help researchers detect mutations in ...

Roche develops new research test kits for omicron variant

San Jose, California (PRWEB) December 01, 2021 -- Specific Diagnostics today announced the appointment of Scott O’Brien as its Chief Commercial Officer. Mr.